Hillevax
large clinical program demonstrates immunogenicity efficacy and safety tolerability | Hillevax
Company
Deck Type
IPO
Sector
Industry
Deck date
April 2022
Slide
13 of 24
Related slides by other companies
BenevolentAI
Investor Presentation
October 2022
ben phase safety and tolerability study successfully completed phase double blind placebo controlled in patient two part clinical study phase first in human dose phase completed mild moderate patients years per cohort ben placebo safety tolerability adaptive multiple ascending dose cohort design includes imaging to evaluate human skin phase successfully completed safety and tolerability arm adaptive design for phase of the clinical study | BenevolentAI
Aeglea BioTherapeutics
Investor Presentation
August 2020
demonstrates durable clinical response at week analysis | Aeglea BioTherapeutics
Fusion Pharmaceuticals
Investor Presentation
November 2023
fusion phase actinium program has achieved clinical a | Fusion Pharmaceuticals
Aeglea BioTherapeutics
Results
May 2020
demonstrates durable clinical response at week analysis achievement of in one or more of three | Aeglea BioTherapeutics
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io